Emerging role of the gut microbiome in post-infectious irritable bowel syndrome:A literature review

作     者：Vasile Valeriu Lupu Cristina Mihaela Ghiciuc Gabriela Stefanescu Cristina Maria Mihai Alina Popp Maria Oana Sasaran Laura Bozomitu Iuliana Magdalena Starcea Anca Adam Raileanu Ancuta Lupu 

作者机构：Faculty of General Medicine“Grigore T.Popa”University of Medicine and PharmacyIasi 700115Romania Faculty of General MedicineOvidius UniversityConstanta 900470Romania Faculty of General Medicine“Carol Davila”University of Medicine and PharmacyBucharest 020021Romania Faculty of General Medicine“George Emil Palade”University of MedicinePharmacyScience and TechnologyTargu Mures 540142Romania 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2023年第29卷第21期

页      面：3241-3256页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

主　　题：Gut microbiome Infectious gastroenteritis Irritable bowel syndrome Post infection syndrome Pathophysiology Inflammation 

摘      要：Post-infectious irritable bowel syndrome(PI-IBS)is a particular type of IBS,with symptom onset after an acute episode of infectious gastroenteritis.Despite infectious disease resolution and clearance of the inciting pathogen agent,10%of patients will develop PI-IBS.In susceptible individuals,the exposure to pathogenic organisms leads to a marked shift in the gut microbiota with prolonged changes in host-microbiota interactions.These changes can affect the gut-brain axis and the visceral sensitivity,disrupting the intestinal barrier,altering neuromuscular function,triggering persistent low inflammation,and sustaining the onset of IBS symptoms.There is no specific treatment strategy for PI-IBS.Different drug classes can be used to treat PI-IBS similar to patients with IBS in general,guided by their clinical symptoms.This review summarizes the current evidence for microbial dysbiosis in PI-IBS and analyzes the available data regarding the role of the microbiome in mediating the central and peripheral dysfunctions that lead to IBS symptoms.It also discusses the current state of evidence on therapies targeting the microbiome in the management of PI-IBS.The results of microbial modulation strategies used in relieving IBS symptomatology are encouraging.Several studies on PI-IBS animal models reported promising results.However,published data that describe the efficacy and safety of microbial targeted therapy in PI-IBS patients are scarce.Future research is required.